In recent years, Advanced Therapy Medicinal Products (ATMP) have evolved into a promising and highly hoped-for medical approach to cure a broad spectrum of inherited and acquired human diseases, ranging from cancer to immunological disorders and rare diseases. However, the path from development to clinical application is not yet routine.
The conference will highlight the challenging field of gene and cell therapeutics.
Advances in development and manufacturing will be presented at ATMP 2021, as well as quality control methods and regulatory aspects: The focus is on the path to safe and beneficial advanced therapies for the patient.
You are cordially invited to contribute to the scientific programme. Abstract submissions are possible until August 18th, 2020.
Please prepare 1-2 pages (incl. figures, max. size 1 MB, max. 2 pages). The abstract should explicitly mention objectives, new results and conclusions or significance of the work.
Accepted abstracts will be published for all conference participants in a book of abstracts (PDF). The congress language is English.
Please use the Template to correctly format your contribution and upload it as PDF file.
Enter the author list (author and co-author/s) and affiliations in the same order as in your abstract.
Please note: DECHEMA will not make any adjustments regarding the author information. The information will be used for the conference documents as given.
The selection of the presentations (lectures and posters) will be based on the review of the abstracts by the Scientific Committee.
Please note: Registration fee cannot be waived for authors.
1) No VAT requested according to § 4.22 UStG, registration fee may include Business Package with VAT.
2) Personal DECHEMA-, VDI-GVC-members and EFC/EFCE passport holders; personal VAAM members
The DECHEMA terms and conditions for conferences apply. Please note that the following informations are excerpts and supplements to the general terms and conditions.
Registration is possible, subject to capacity in the lecture rooms, up to the beginning of the conference. Confirmation of registration will be sent immediately by mail. The invoice, with payment confirmation, you will receive by post mail within two weeks.
Editorial deadline for the list of participants is 31 January 2021.
The registration fees include conference ticket, book of abstracts and list of participants.
All documents will be handed out on-site.
Cancellations are only accepted in writing (i.e. by fax, surface mail or e-mail).
Please find details about cancellation dates and fees in the general terms and conditions. In case of no-show the conference fees won't be refunded and fees not yet paid still have to be paid.
For companies / institutions interested in exhibiting at the ATMP 2021 conference, we offer the following standard package:
Exhibition package: 1.200,00 € (excluding VAT)
The exhibition area is located in the foyer of the lecture hall and close to the catering area.
The conference will highlight the challenging field of gene and cell therapeutic approaches, especially focusing on the following topics:
We are very pleased to announce the following keynote speakers:
Paula M. Alves
Keynote Lecture: Stem Cells for Drug Discovery and Therapy: Bioprocessing Challenges
Keynote Lecture: Advanced Therapy Manufacturing: Regulatory Challenges in an Innovative Landscape
Keynote Lecture: IMI, an opportunity for R&D in ATMP
Ulf Bethke Miltenyi Biotec GmbH, Bergisch Gladbach
Cornelia Kasper University of Natural Resources and Life Sciences, Vienna
Konrad Kohler BioMedTech, Forschungscampus Reutlingen
Thomas Noll University of Bielefeld
Ralf Pörtner Technical University Hamburg
Bernd Schröder Miltenyi Biotec GmbH, Teterow
Karin Tiemann DECHEMA e.V., Frankfurt am Main
Andrea Traube OPTIMA pharma GmbH, Schwäbisch Hall
Roland Wagner Technical University Braunschweig
Directions to DECHEMA: Please find a detailed description at www.dechema.de/location.
DECHEMA is located in a so called "Umweltzone" in the city of Frankfurt. If you intend to reach us by car, you need the corresponding green sticker on your car. More information available in German language at www.umweltzone.frankfurt.de.
Parking capacities at DECHEMA are very limited. Please use public parking lots along Theodor-Heuss-Allee: Congress-Center-Messe (CMF) or at the fair tower (Messeturm).
Going to DECHEMA by train? Use the joint offer from Deutsche Bahn (DB) and DECHEMA and travel to our events with reduced fares.
We recommend you the following hotels. We have not reserved any contingent of rooms. Please book a room by yourself. When using the booking code you will get a special rate.
Maritim Hotel Frankfurt (5 min walking distance)
60486 Frankfurt am Main
Phone: 0049 69 75 78-1134
Single room: around 108 EUR per night and incl. breakfast and wifi.
Please ask us for the booking code of the Maritim Hotel.
Mercure Hotel (10 min walking distance)
60486 Frankfurt am Main
Phone: 0049 69 7926 0
Single room: around 107 EUR per night and incl. breakfast and wifi.
You can book your rooms directly with the booking code "DECHEMA".
HOTEL FRANKFURT MESSE managed by Meliá Hotels International (15min walking distance)
60486 Frankfurt am Main
Phone: 0049 69 70730500
Single room: around 92 EUR incl. breakfast and wifi.
You can book your rooms directly with the booking code "DECHEMA" or 1277408 (Online-Booking)
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
The challenges and issues of manufacturing and analytics of gene and cell therapeutics are very different from all other therapeutics, including biopharmaceuticals. A key factor of success is the management of multiple challenges addressing safety, purity and potency of these advanced therapies.
Robust and reliable manufacturing processes are still far from routine. Efficient gene transfer vectors, delivering the therapeutic gene into the target cells without causing any associated pathogenic effect, need to be developed and produced in large-scale.
Depending on the complexity and individuality of this product class, cell therapy manufacturing processes may comprise consistent procedures of culture, expansion, genetic manipulation, stimulation, and in case of treatments of multiple patients, cell banking. Analytics and quality control need to be adapted to this broad range of complex manufacturing processes ensuring adequate safety, purity and potency of the final products.
The conference is an initiative of the DECHEMA working groups Cell Culture Technology and Medical Biotechnology.